Next-Generation DMSO-Free & Serum-Free Cryopreservation For Cell And Gene Therapy Manufacturing And Processing

Listen in on this discussion about the latest developments in cryopreservation technologies and how they can revolutionize cell and gene therapy manufacturing, processing, and their implications for clinical implementation. Emphasis will be placed on novel DMSO-free and serum-free cryopreservation solutions and provide insights into how they can improve the quality and efficacy of raw materials, intermediates and final products in the cell and gene therapy space.

The regenerative medicine field is rapidly advancing, with many pivotal trials underway. Particularly for large-scale commercial manufacturing, cryopreservation is becoming a crucial component to ensure a longer shelf-life throughout production, resilient logistics to transport, and ultimately maximum therapeutic efficacy during administration. However, the efficacy and yield of sensitive cell types such as induced pluripotent stem cells and genetically engineered cell-based immunotherapies are significantly limited due to ice formation and consequent damage, as well as genomic and in vivo toxicity associated with current cryoprotectants (e.g., DMSO). These problems further limit the realization of standard products in modern regenerative medicine as developed in allogeneic cell therapy and tissue engineering.

In this webinar, we cover the emerging use of novel biomimetic molecules, known as peptoids, that are modeled after naturally occurring anti-freeze proteins. As the industry continues to wrestle with DMSO-related challenges from a manufacturing, logistical and clinical perspective, webinar attendees will gain insight into the paradigm shift enabled by these superior ice-binding molecules, and how they have the potential to dramatically improve large-scale regenerative medicine manufacturing and enable the distribution of temperature-sensitive cell and gene therapy products without any geographic restrictions.